90 related articles for article (PubMed ID: 22029645)
1. Normocalcaemic normomagnesaemic tetany with tacrolimus.
Aiyangar A; Chowdhary P; Rao K; Kiran K
Nephrology (Carlton); 2011 Nov; 16(8):784-5. PubMed ID: 22029645
[No Abstract] [Full Text] [Related]
2. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure.
Connor A; Prowse A; MacPhee I; Rowe PA
Transplantation; 2012 Jun; 93(12):e45-6. PubMed ID: 23318306
[No Abstract] [Full Text] [Related]
3. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant.
Ogunseinde BA; Wimmers E; Washington B; Iyob M; Cropper T; Callender CO
Transplantation; 2003 Jul; 76(2):448. PubMed ID: 12883222
[No Abstract] [Full Text] [Related]
4. Acquired Glanzmann's thrombasthenia variant and immune thrombocytopenia in a renal transplant recipient receiving tacrolimus.
Morath C; Hoffmann T; Kirchhoff EM; Sis J; Zeier M; Scharf RE; Andrassy K
Thromb Haemost; 2005 Oct; 94(4):879-80. PubMed ID: 16270646
[No Abstract] [Full Text] [Related]
5. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
Alhamad T; Venkatachalam K; Daloul R; Brennan DC; Malone AF
Transplantation; 2017 Aug; 101(8):e287-e288. PubMed ID: 28422926
[No Abstract] [Full Text] [Related]
6. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
Kuypers DR
Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
[No Abstract] [Full Text] [Related]
7. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B
J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
[TBL] [Abstract][Full Text] [Related]
8. [Immunosuppressive agents in kidney transplantation].
Nishi S
Nihon Jinzo Gakkai Shi; 2011; 53(1):1-5. PubMed ID: 21370569
[No Abstract] [Full Text] [Related]
9. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
10. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus in kidney transplantation.
Kliem V; Brunkhorst R
Contrib Nephrol; 1998; 124():103-16; discussion 116-25. PubMed ID: 9761977
[No Abstract] [Full Text] [Related]
12. Preliminary experience with FK 506 in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Castaldo P; Sindhi R; Sudan D; Frisbie K; Cushing K
Transplant Proc; 1995 Dec; 27(6):3024. PubMed ID: 8539823
[No Abstract] [Full Text] [Related]
13. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
van Gelder T; Hesselink DA
Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
[TBL] [Abstract][Full Text] [Related]
14. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
Chadban S
Nephrol Dial Transplant; 2008 Jun; 23(6):1816-8. PubMed ID: 18326882
[No Abstract] [Full Text] [Related]
15. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
16. [Importance of erythrocyte magnesium in the diagnosis and treatment of certain tetanies].
Schirardin H; Misson C
Sem Hop; 1967 Dec; 43(51):3252-7. PubMed ID: 4299869
[No Abstract] [Full Text] [Related]
17. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
18. Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation.
Walder B; Ricou B; Suter PM
J Heart Lung Transplant; 1998 Oct; 17(10):1004-6. PubMed ID: 9811409
[TBL] [Abstract][Full Text] [Related]
19. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
[No Abstract] [Full Text] [Related]
20. [Immunosuppression and the problems in partial liver transplantation].
Kawasaki M; Hashikura Y; Matsunami H; Makunouchi M
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):683. PubMed ID: 8963785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
